|
시장보고서
상품코드
1762458
세계의 유전자 치료 플랫폼 시장, 규모, 점유율, 동향 분석 보고서 : 플랫폼 유형별, 용도별, 전달 모드별, 최종 용도별, 지역별 - 시장 예측(2025-2034년)Gene Therapy Platform Market Size, Share, & Trends Analysis Report: By Platform Type, By Application, By Delivery Mode (In Vivo, Ex Vivo, and Other), By End Use, and By Region - Market Forecast, 2025-2034 |
||||||
Polaris Market Research의 최신 조사에 따르면, 유전자 치료 플랫폼 시장 규모는 2034년까지 110억 3,541만 달러에 달할 것으로 예측됩니다. 이 보고서는 현재 시장 역학에 대한 자세한 통찰력과 미래 시장 성장에 대한 분석을 제공합니다.
유전자 치료 플랫폼은 질병의 치료나 예방을 위해 결함 유전자를 교정하거나 대체하는 유전자 기반 치료법을 개발, 제공, 제조하는 데 사용되는 종합적인 시스템 및 기술입니다. 유전자 치료에 대한 투자가 급증하고 있으며, 정부, 벤처 캐피탈, 제약회사에서 수백만 달러가 연구개발에 투입되고 있습니다. 이러한 재정적 지원을 통해 바이오테크 스타트업과 연구기관은 보다 신속하게 기술 혁신을 수행하고, 임상시험을 수행하며, 새로운 치료법을 시장에 출시할 수 있습니다. 희귀질환과 중증질환을 치료할 수 있는 유전자 치료의 높은 잠재력은 투자자들에게 매력적인 분야가 되고 있습니다. 기업 간 인수합병과 공동연구가 증가하고 있으며, 이는 보다 강력한 플랫폼과 파이프라인을 구축하는 데 도움이 되고 있습니다. 유전자 치료 기술을 발전시키고 더 많은 환자들에게 전 세계적으로 적용 범위를 확대하기 위해서는 이러한 강력한 재정적 뒷받침이 필수적입니다.
유전자 치료 제품의 임상시험 성공 사례와 규제 당국의 승인 건수가 증가함에 따라 이 치료법에 대한 신뢰가 높아지고 있습니다. 척수성 근위축증에 대한 졸겐스마나 유전성 시력저하증에 대한 룩스투르나와 같은 치료법은 유망하고 종종 삶을 변화시키는 결과를 보여주고 있습니다. 긍정적인 시험 결과는 실제 세계에서 안전성과 유효성을 입증하고 연구와 투자를 촉진하는 데 도움이 됩니다. 더 많은 치료법이 승인되면 유전자 치료의 잠재력이 입증되고 의사, 환자, 지불자에게 널리 받아들여질 것입니다. 이러한 성공은 차세대 치료의 길을 열고, 유전자 치료 플랫폼 시장에 활력을 불어넣고, 그 영역을 넓혀가고 있습니다.
유전자 치료 플랫폼 시장 보고서 하이라이트
2024년 바이러스 벡터 플랫폼 부문은 세포 내 유전물질 도입 효율이 높아 가장 큰 점유율을 차지했습니다.
신경질환 분야는 파킨슨병, 척수성 근위축증(SMA), 헌팅턴병과 같은 질환의 치료를 획기적으로 변화시킬 수 있는 큰 잠재력을 지닌 유전자 치료의 주요 응용 분야로 큰 성장이 기대되는 분야입니다.
2024년에는 북미가 유전자 치료 플랫폼 시장에서 가장 큰 점유율을 차지했습니다. 이 지역은 선진적인 의료 인프라, 강력한 정부 지원, 제약 및 생명공학 기업의 높은 R&D 비용의 혜택을 누리고 있기 때문입니다.
아시아태평양의 유전자 치료 플랫폼 시장은 헬스케어 투자 증가, 생명공학 분야 확대, 규제 체계 개선으로 인해 큰 성장을 보이고 있습니다.
세계 주요 시장 기업으로는 Andelyn Biosciences, AstraZeneca, Autolomous Ltd, BioIT, DEEP GENOMICS, ElevateBio, IBM, IDBS, L7 Informatics, Lonza, Novartis, Precision BioSciences, Renova Therapeutics, SAP SE, Sarepta Therapeutics, TrakCare, Novartis, SAP SE, Sarepta Therapeutics, TrakCare, Novartis, Precision BioSciences, Sarepta Therapeutics, SAP SE, SAP, Traxa Therapeutics, TrakCare, Traxa Therapeutics, TrakCare Novartis, Precision BioSciences, Renova Therapeutics, SAP SE, Sarepta Therapeutics, TrakCel 등이 있습니다.
목차
제1장 서론
제2장 주요 요약
제3장 조사 방법
제4장 세계의 유전자 치료 플랫폼 시장 인사이트
- 시장 현황
- 유전자 치료 플랫폼 시장 역학
- 성장 촉진요인과 기회
- 성장 억제요인과 과제
- PESTEL 분석
- 유전자 치료 플랫폼 시장 동향
- 밸류체인 분석
제5장 세계의 유전자 치료 플랫폼 시장 : 플랫폼별
- 주요 조사 결과
- 서론
- 바이러스 벡터 플랫폼
- 비바이러스 벡터 플랫폼
- 유전자 편집 플랫폼
- CRISPR-Cas 시스템
- TALENs
- ZFN
제6장 세계의 유전자 치료 플랫폼 시장 : 용도별
- 주요 조사 결과
- 서론
- 종양학
- 희소 유전성 질환
- 심혈관질환
- 신경질환
- 안과질환
- 혈액질환
- 근골격계 장애
- 감염증
제7장 세계의 유전자 치료 플랫폼 시장 : 전달 모드별
- 주요 조사 결과
- 서론
- 생체내
- 생체외
- 기타
제8장 세계의 유전자 치료 플랫폼 시장 : 최종 용도별
- 주요 조사 결과
- 서론
- 제약 기업 및 바이오테크놀러지 기업
- 학술연구기관
- 계약 개발 제조 조직(CDMO)
- 병원 및 유전자 치료 센터
제9장 세계의 유전자 치료 플랫폼 시장 : 지역별
- 주요 조사 결과
- 서론
- 유전자 치료 플랫폼 시장 평가 : 지역, 2020년-2034년
- 북미
- 북미 : 플랫폼별, 2020년-2034년
- 북미 : 용도별, 2020년-2034년
- 북미 : 전달 모드별, 2020년-2034년
- 북미 : 최종 용도별, 2020년-2034년
- 미국
- 캐나다
- 유럽
- 유럽 : 플랫폼별, 2020년-2034년
- 유럽 : 용도별, 2020년-2034년
- 유럽 : 전달 모드별, 2020년-2034년
- 유럽 : 최종 용도별, 2020년-2034년
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
- 기타 유럽
- 아시아태평양
- 아시아태평양 : 플랫폼별, 2020년-2034년
- 아시아태평양 : 용도별, 2020년-2034년
- 아시아태평양 : 전달 모드별, 2020년-2034년
- 아시아태평양 : 최종 용도별, 2020년-2034년
- 중국
- 인도
- 말레이시아
- 일본
- 인도네시아
- 한국
- 호주
- 기타 아시아태평양
- 중동 및 아프리카
- 중동 및 아프리카 : 플랫폼별, 2020년-2034년
- 중동 및 아프리카 : 용도별, 2020년-2034년
- 중동 및 아프리카 : 전달 모드별, 2020년-2034년
- 중동 및 아프리카 : 최종 용도별, 2020년-2034년
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 남아프리카공화국
- 기타 중동 및 아프리카
- 라틴아메리카
- 라틴아메리카 : 플랫폼별, 2020년-2034년
- 라틴아메리카 : 용도별, 2020년-2034년
- 라틴아메리카 : 전달 모드별, 2020년-2034년
- 라틴아메리카 : 최종 용도별, 2020년-2034년
- 멕시코
- 브라질
- 아르헨티나
- 기타 라틴아메리카
제10장 경쟁 구도
- 확대와 인수 분석
- 확대
- 인수
- 제휴/협업/합의/공개
제11장 기업 개요
- Andelyn Biosciences
- AstraZeneca
- Autolomous Ltd
- BioIT
- DEEP GENOMICS
- ElevateBio
- IBM
- IDBS
- L7 Informatics, Inc.
- Lonza
- Novartis
- Precision BioSciences
- Renova Therapeutics
- SAP SE
- Sarepta Therapeutics, Inc.
- TrakCel
The gene therapy platform market size is expected to reach USD 11,035.41 million by 2034, according to a new study by Polaris Market Research. The report "Gene Therapy Platform Market Size, Share, & Trends Analysis Report: By Platform Type, By Application, By Delivery Mode (In Vivo, Ex Vivo, and Other), By End Use, and By Region - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
A gene therapy platform is a comprehensive system or technology used to develop, deliver, and manufacture gene-based treatments that modify or replace faulty genes to treat or prevent diseases. Investments in gene therapy have surged, with millions of dollars flowing from governments, venture capitalists, and pharmaceutical companies into research and development. This financial support enables biotech startups and research institutions to innovate faster, conduct clinical trials, and bring new therapies to market. The high potential of gene therapy to cure rare and serious diseases makes it an attractive area for investors. Mergers and acquisitions, and collaborations among companies are increasing, helping to build stronger platforms and pipelines. This strong financial backing is essential for advancing gene therapy technologies and expanding their reach to more patients globally.
The increasing number of successful clinical trials and regulatory approvals for gene therapy products boosts confidence in this treatment approach. Therapies such as Zolgensma for spinal muscular atrophy and Luxturna for inherited vision loss have shown promising, often life-changing results. Positive trial outcomes demonstrate real-world safety and effectiveness, encouraging research and investment. As more therapies receive approval, it validates the potential of gene therapy and drives broader acceptance by doctors, patients, and payers. These successes are paving the way for a new generation of treatments, creating momentum and expanding the scope of the gene therapy platform market.
Gene Therapy Platform Market Report Highlights
In 2024, the viral vector platforms segment dominated with the largest share due to their high efficiency in delivering genetic material into cells.
The neurological disorders segment is expected to experience significant growth as it is a major application area for gene therapy, with significant potential to transform treatment for diseases such as Parkinson's, spinal muscular atrophy (SMA), and Huntington's disease.
In 2024, the North America gene therapy platform market dominated with the largest share as the region benefits from advanced healthcare infrastructure, strong government support, and high R&D spending by pharmaceutical and biotech companies.
The Asia Pacific gene therapy platform market is experiencing significant growth due to rising healthcare investments, expanding biotech sectors, and improving regulatory frameworks.
A few global key market players are Andelyn Biosciences; AstraZeneca; Autolomous Ltd; BioIT; DEEP GENOMICS; ElevateBio; IBM; IDBS; L7 Informatics, Inc.; Lonza; Novartis; Precision BioSciences; Renova Therapeutics; SAP SE; Sarepta Therapeutics, Inc.; and TrakCel.
Polaris Market Research has segmented the gene therapy platform market report on the basis of platform type, application, delivery mode, end use, and region:
By Platform Type (Revenue - USD Million, 2020-2034)
Viral Vector Platforms
Adeno-Associated Virus (AAV)
Lentivirus
Retrovirus
Adenovirus
Herpes Simplex Virus (HSV)
Non-Viral Vector Platforms
Lipid Nanoparticles (LNPs)
Electroporation & Microinjection Platforms
Polymer-Based Delivery Systems
Naked DNA/RNA Delivery
Gene Editing Platforms
CRISPR-Cas Systems
TALENs
ZFNs
By Application (Revenue - USD Million, 2020-2034)
Oncology
Rare Genetic Disorders
Cardiovascular Diseases
Neurological Disorders
Ophthalmic Diseases
Hematological Disorders
Musculoskeletal Disorders
Infectious Diseases
By Delivery Mode (Revenue - USD Million, 2020-2034)
In Vivo
Ex Vivo
Other
By End Use (Revenue - USD Million, 2020-2034)
Pharmaceutical & Biotechnology Companies
Academic & Research Institutions
Contract Development & Manufacturing Organizations (CDMOs)
Hospitals & Gene Therapy Centers
By Regional Outlook (Revenue - USD Million, 2020-2034)
North America
US
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Asia Pacific
China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Vietnam
Rest of Asia Pacific
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Rest of Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Gene Therapy Platform Market Insights
- 4.1. Gene Therapy Platform Market - Market Snapshot
- 4.2. Gene Therapy Platform Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Rising Demand for Personalized Medicine
- 4.2.1.2. Growing Prevalence of Genetic Disorder
- 4.2.2. Restraints and Challenges
- 4.2.2.1. High Initial Investment
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Gene Therapy Platform Market Trends
- 4.6. Value Chain Analysis
5. Global Gene Therapy Platform Market, by Platform
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
- 5.3. Viral Vector Platforms
- 5.3.1. Global Gene Therapy Platform Market, by Viral Vector Platforms, by Region, 2020-2034 (USD Million)
- 5.3.2. Adeno-associated Virus (AAV)
- 5.3.2.1. Global Gene Therapy Platform Market, by Adeno-associated Virus (AAV), by Region, 2020-2034 (USD Million)
- 5.3.3. Lentivirus
- 5.3.3.1. Global Gene Therapy Platform Market, by Lentivirus, by Region, 2020-2034 (USD Million)
- 5.3.4. Retrovirus
- 5.3.4.1. Global Gene Therapy Platform Market, by Retrovirus, by Region, 2020-2034 (USD Million)
- 5.3.5. Adenovirus
- 5.3.5.1. Global Gene Therapy Platform Market, by Adenovirus, by Region, 2020-2034 (USD Million)
- 5.3.6. Herpes Simplex Virus (HSV)
- 5.3.6.1. Global Gene Therapy Platform Market, by Herpes Simplex Virus (HSV), by Region, 2020-2034 (USD Million)
- 5.4. Non-Viral Vector Platforms
- 5.4.1. Global Gene Therapy Platform Market, by Non-Viral Vector Platforms, by Region, 2020-2034 (USD Million)
- 5.4.2. Lipid Nanoparticles (LNPs)
- 5.4.2.1. Global Gene Therapy Platform Market, by Lipid Nanoparticles (LNPs), by Region, 2020-2034 (USD Million)
- 5.4.3. Electroporation & Microinjection Platforms
- 5.4.3.1. Global Gene Therapy Platform Market, by Electroporation & Microinjection Platforms by Region, 2020-2034 (USD Million)
- 5.4.4. Polymer-based Delivery Systems
- 5.4.4.1. Global Gene Therapy Platform Market, by Polymer-based Delivery Systems by Region, 2020-2034 (USD Million)
- 5.4.5. Naked DNA/RNA Delivery
- 5.4.5.1. Global Gene Therapy Platform Market, by Naked DNA/RNA Delivery by Region, 2020-2034 (USD Million)
- 5.5. Gene Editing Platforms
- 5.5.1. Global Gene Therapy Platform Market, by Gene Editing Platforms by Region, 2020-2034 (USD Million)
- 5.6. CRISPR-Cas Systems
- 5.6.1. Global Gene Therapy Platform Market, by CRISPR-Cas Systems by Region, 2020-2034 (USD Million)
- 5.7. TALENs
- 5.7.1. Global Gene Therapy Platform Market, by TALENs by Region, 2020-2034 (USD Million)
- 5.8. ZFNs
- 5.8.1. Global Gene Therapy Platform Market, by ZFNs by Region, 2020-2034 (USD Million)
- 5.8.2.
6. Global Gene Therapy Platform Market, by Application
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
- 6.3. Oncology
- 6.3.1. Global Gene Therapy Platform Market, by Oncology, by Region, 2020-2034 (USD Million)
- 6.4. Rare Genetic Disorders
- 6.4.1. Global Gene Therapy Platform Market, by Rare Genetic Disorders, by Region, 2020-2034 (USD Million)
- 6.5. Cardiovascular Diseases
- 6.5.1. Global Gene Therapy Platform Market, by Cardiovascular Diseases, by Region, 2020-2034 (USD Million)
- 6.6. Neurological Disorders
- 6.6.1. Global Gene Therapy Platform Market, by Neurological Disorders, by Region, 2020-2034 (USD Million)
- 6.7. Ophthalmic Diseases
- 6.7.1. Global Gene Therapy Platform Market, by Ophthalmic Diseases, by Region, 2020-2034 (USD Million)
- 6.8. Hematological Disorders
- 6.8.1. Global Gene Therapy Platform Market, by Hematological Disorders, by Region, 2020-2034 (USD Million)
- 6.9. Musculoskeletal Disorders
- 6.9.1. Global Gene Therapy Platform Market, by Musculoskeletal Disorders, by Region, 2020-2034 (USD Million)
- 6.10. Infectious Diseases
- 6.10.1. Global Gene Therapy Platform Market, by Infectious Diseases, by Region, 2020-2034 (USD Million)
7. Global Gene Therapy Platform Market, by Delivery Mode
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Gene Therapy Platform Market, by Medical Biotechnology, 2020-2034 (USD Million)
- 7.3. In Vivo
- 7.3.1. Global Gene Therapy Platform Market, by In Vivo, by Region, 2020-2034 (USD Million)
- 7.4. Ex Vivo
- 7.4.1. Global Gene Therapy Platform Market, by Ex Vivo, by Region, 2020-2034 (USD Million)
- 7.5. Other
- 7.5.1. Global Gene Therapy Platform Market, by Other, by Region, 2020-2034 (USD Million)
8. Global Gene Therapy Platform Market, by End Use
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. Global Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
- 8.3. Pharmaceutical & Biotechnology Companies
- 8.3.1. Global Gene Therapy Platform Market, by Pharmaceutical & Biotechnology Companies, by Region, 2020-2034 (USD Million)
- 8.4. Academic & Research Institutions
- 8.4.1. Global Gene Therapy Platform Market, by Academic & Research Institutions, by Region, 2020-2034 (USD Million)
- 8.5. Contract Development & Manufacturing Organizations (CDMOs)
- 8.5.1. Global Gene Therapy Platform Market, by Contract Development & Manufacturing Organizations (CDMOs), 2020-2034 (USD Million)
- 8.6. Hospitals & Gene Therapy Centers
- 8.6.1. Global Gene Therapy Platform Market, by Hospitals & Gene Therapy Centers, by Region, 2020-2034 (USD Million)
9. Global Gene Therapy Platform Market, by Geography
- 9.1. Key Findings
- 9.2. Introduction
- 9.2.1. Gene Therapy Platform Market Assessment, By Geography, 2020-2034 (USD Million)
- 9.3. Gene Therapy Platform Market - North America
- 9.3.1. North America: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
- 9.3.2. North America: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
- 9.3.3. North America: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
- 9.3.4. North America: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
- 9.3.5. Gene Therapy Platform Market - US
- 9.3.5.1. US: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
- 9.3.5.2. US: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
- 9.3.5.3. US: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
- 9.3.5.4. US: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
- 9.3.6. Gene Therapy Platform Market - Canada
- 9.3.6.1. Canada: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
- 9.3.6.2. Canada: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
- 9.3.6.3. Canada: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
- 9.3.6.4. Canada: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
- 9.4. Gene Therapy Platform Market - Europe
- 9.4.1. Europe: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
- 9.4.2. Europe: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
- 9.4.3. Europe: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
- 9.4.4. Europe: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
- 9.4.5. Gene Therapy Platform Market - UK
- 9.4.5.1. UK: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
- 9.4.5.2. UK: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
- 9.4.5.3. UK: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
- 9.4.5.4. UK: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
- 9.4.6. Gene Therapy Platform Market - France
- 9.4.6.1. France: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
- 9.4.6.2. France: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
- 9.4.6.3. France: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
- 9.4.6.4. France: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
- 9.4.7. Gene Therapy Platform Market - Germany
- 9.4.7.1. Germany: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
- 9.4.7.2. Germany: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
- 9.4.7.3. Germany: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
- 9.4.7.4. Germany: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
- 9.4.8. Gene Therapy Platform Market - Italy
- 9.4.8.1. Italy: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
- 9.4.8.2. Italy: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
- 9.4.8.3. Italy: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
- 9.4.8.4. Italy: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
- 9.4.9. Gene Therapy Platform Market - Spain
- 9.4.9.1. Spain: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
- 9.4.9.2. Spain: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
- 9.4.9.3. Spain: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
- 9.4.9.4. Spain: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
- 9.4.10. Gene Therapy Platform Market - Netherlands
- 9.4.10.1. Netherlands: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
- 9.4.10.2. Netherlands: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
- 9.4.10.3. Netherlands: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
- 9.4.10.4. Netherlands: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
- 9.4.11. Gene Therapy Platform Market - Russia
- 9.4.11.1. Russia: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
- 9.4.11.2. Russia: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
- 9.4.11.3. Russia: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
- 9.4.11.4. Russia: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
- 9.4.12. Gene Therapy Platform Market - Rest of Europe
- 9.4.12.1. Rest of Europe: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
- 9.4.12.2. Rest of Europe: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
- 9.4.12.3. Rest of Europe: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
- 9.4.12.4. Rest of Europe: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
- 9.5. Gene Therapy Platform Market - Asia Pacific
- 9.5.1. Asia Pacific: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
- 9.5.2. Asia Pacific: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
- 9.5.3. Asia Pacific: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
- 9.5.4. Asia Pacific: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
- 9.5.5. Gene Therapy Platform Market - China
- 9.5.5.1. China: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
- 9.5.5.2. China: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
- 9.5.5.3. China: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
- 9.5.5.4. China: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
- 9.5.6. Gene Therapy Platform Market - India
- 9.5.6.1. India: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
- 9.5.6.2. India: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
- 9.5.6.3. India: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
- 9.5.6.4. India: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
- 9.5.7. Gene Therapy Platform Market - Malaysia
- 9.5.7.1. Malaysia: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
- 9.5.7.2. Malaysia: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
- 9.5.7.3. Malaysia: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
- 9.5.7.4. Malaysia: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
- 9.5.8. Gene Therapy Platform Market - Japan
- 9.5.8.1. Japan: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
- 9.5.8.2. Japan: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
- 9.5.8.3. Japan: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
- 9.5.8.4. Japan: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
- 9.5.9. Gene Therapy Platform Market - Indonesia
- 9.5.9.1. Indonesia: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
- 9.5.9.2. Indonesia: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
- 9.5.9.3. Indonesia: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
- 9.5.9.4. Indonesia: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
- 9.5.10. Gene Therapy Platform Market - South Korea
- 9.5.10.1. South Korea: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
- 9.5.10.2. South Korea: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
- 9.5.10.3. South Korea: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
- 9.5.10.4. South Korea: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
- 9.5.11. Gene Therapy Platform Market - Australia
- 9.5.11.1. Australia: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
- 9.5.11.2. Australia: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
- 9.5.11.3. Australia: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
- 9.5.11.4. Australia: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
- 9.5.12. Gene Therapy Platform Market - Rest of Asia Pacific
- 9.5.12.1. Rest of Asia Pacific: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
- 9.5.12.2. Rest of Asia Pacific: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
- 9.5.12.3. Rest of Asia Pacific: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
- 9.5.12.4. Rest of Asia Pacific: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
- 9.6. Gene Therapy Platform Market - Middle East & Africa
- 9.6.1. Middle East & Africa: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
- 9.6.2. Middle East & Africa: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
- 9.6.3. Middle East & Africa: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
- 9.6.4. Middle East & Africa: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
- 9.6.5. Gene Therapy Platform Market - Saudi Arabia
- 9.6.5.1. Saudi Arabia: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
- 9.6.5.2. Saudi Arabia: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
- 9.6.5.3. Saudi Arabia: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
- 9.6.5.4. Saudi Arabia: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
- 9.6.6. Gene Therapy Platform Market - UAE
- 9.6.6.1. UAE: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
- 9.6.6.2. UAE: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
- 9.6.6.3. UAE: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
- 9.6.6.4. UAE: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
- 9.6.7. Gene Therapy Platform Market - Israel
- 9.6.7.1. Israel: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
- 9.6.7.2. Israel: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
- 9.6.7.3. Israel: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
- 9.6.7.4. Israel: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
- 9.6.8. Gene Therapy Platform Market - South Africa
- 9.6.8.1. South Africa: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
- 9.6.8.2. South Africa: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
- 9.6.8.3. South Africa: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
- 9.6.8.4. South Africa: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
- 9.6.9. Gene Therapy Platform Market - Rest of Middle East & Africa
- 9.6.9.1. Rest of Middle East & Africa: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
- 9.6.9.2. Rest of Middle East & Africa: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
- 9.6.9.3. Rest of Middle East & Africa: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
- 9.6.9.4. Rest of Middle East & Africa: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
- 9.7. Gene Therapy Platform Market - Latin America
- 9.7.1. Latin America: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
- 9.7.2. Latin America: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
- 9.7.3. Latin America: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
- 9.7.4. Latin America: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
- 9.7.5. Gene Therapy Platform Market - Mexico
- 9.7.5.1. Mexico: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
- 9.7.5.2. Mexico: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
- 9.7.5.3. Mexico: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
- 9.7.5.4. Mexico: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
- 9.7.6. Gene Therapy Platform Market - Brazil
- 9.7.6.1. Brazil: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
- 9.7.6.2. Brazil: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
- 9.7.6.3. Brazil: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
- 9.7.6.4. Brazil: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
- 9.7.7. Gene Therapy Platform Market - Argentina
- 9.7.7.1. Argentina: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
- 9.7.7.2. Argentina: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
- 9.7.7.3. Argentina: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
- 9.7.7.4. Argentina: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
- 9.7.8. Gene Therapy Platform Market - Rest of Latin America
- 9.7.8.1. Rest of Latin America: Gene Therapy Platform Market, by Platform, 2020-2034 (USD Million)
- 9.7.8.2. Rest of Latin America: Gene Therapy Platform Market, by Application, 2020-2034 (USD Million)
- 9.7.8.3. Rest of Latin America: Gene Therapy Platform Market, by Delivery Mode, 2020-2034 (USD Million)
- 9.7.8.4. Rest of Latin America: Gene Therapy Platform Market, by End Use, 2020-2034 (USD Million)
10. Competitive Landscape
- 10.1. Expansion and Acquisition Analysis
- 10.1.1. Expansion
- 10.1.2. Acquisitions
- 10.2. Partnerships/Collaborations/Agreements/Exhibitions
11. Company Profiles
- 11.1. Andelyn Biosciences
- 11.1.1. Company Overview
- 11.1.2. Financial Performance
- 11.1.3. Product Benchmarking
- 11.1.4. Recent Development
- 11.2. AstraZeneca
- 11.2.1. Company Overview
- 11.2.2. Financial Performance
- 11.2.3. Product Benchmarking
- 11.2.4. Recent Development
- 11.3. Autolomous Ltd
- 11.3.1. Company Overview
- 11.3.2. Financial Performance
- 11.3.3. Product Benchmarking
- 11.3.4. Recent Development
- 11.4. BioIT
- 11.4.1. Company Overview
- 11.4.2. Financial Performance
- 11.4.3. Product Benchmarking
- 11.4.4. Recent Development
- 11.5. DEEP GENOMICS
- 11.5.1. Company Overview
- 11.5.2. Financial Performance
- 11.5.3. Product Benchmarking
- 11.5.4. Recent Development
- 11.6. ElevateBio
- 11.6.1. Company Overview
- 11.6.2. Financial Performance
- 11.6.3. Product Benchmarking
- 11.6.4. Recent Development
- 11.7. IBM
- 11.7.1. Company Overview
- 11.7.2. Financial Performance
- 11.7.3. Product Benchmarking
- 11.7.4. Recent Development
- 11.8. IDBS
- 11.8.1. Company Overview
- 11.8.2. Financial Performance
- 11.8.3. Product Benchmarking
- 11.8.4. Recent Development
- 11.9. L7 Informatics, Inc.
- 11.9.1. Company Overview
- 11.9.2. Financial Performance
- 11.9.3. Product Benchmarking
- 11.9.4. Recent Development
- 11.10. Lonza
- 11.10.1. Company Overview
- 11.10.2. Financial Performance
- 11.10.3. Product Benchmarking
- 11.10.4. Recent Development
- 11.11. Novartis
- 11.11.1. Company Overview
- 11.11.2. Financial Performance
- 11.11.3. Product Benchmarking
- 11.11.4. Recent Development
- 11.12. Precision BioSciences
- 11.12.1. Company Overview
- 11.12.2. Financial Performance
- 11.12.3. Product Benchmarking
- 11.12.4. Recent Development
- 11.13. Renova Therapeutics
- 11.13.1. Company Overview
- 11.13.2. Financial Performance
- 11.13.3. Product Benchmarking
- 11.13.4. Recent Development
- 11.14. SAP SE
- 11.14.1. Company Overview
- 11.14.2. Financial Performance
- 11.14.3. Product Benchmarking
- 11.14.4. Recent Development
- 11.15. Sarepta Therapeutics, Inc.
- 11.15.1. Company Overview
- 11.15.2. Financial Performance
- 11.15.3. Product Benchmarking
- 11.15.4. Recent Development
- 11.16. TrakCel
- 11.16.1. Company Overview
- 11.16.2. Financial Performance
- 11.16.3. Product Benchmarking
- 11.16.4. Recent Development
